Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by investment analysts at Robert W. Baird in a report released on Friday.

Other analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. BidaskClub upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $15.38.

Shares of Karyopharm Therapeutics (KPTI) traded up $0.87 during mid-day trading on Friday, reaching $11.23. The company’s stock had a trading volume of 2,269,911 shares, compared to its average volume of 176,495.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 75.03% and a negative net margin of 67,267.47%. equities analysts predict that Karyopharm Therapeutics will post -2.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/karyopharm-therapeutics-inc-kpti-earns-buy-rating-from-robert-w-baird.html.

In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 10,695 shares of company stock valued at $118,950 over the last 90 days. 14.71% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Candriam Luxembourg S.C.A. grew its holdings in shares of Karyopharm Therapeutics by 16.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after buying an additional 72,000 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Karyopharm Therapeutics by 396.0% during the third quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock worth $1,160,000 after buying an additional 84,362 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Karyopharm Therapeutics by 12.2% during the second quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock worth $542,000 after buying an additional 6,500 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Karyopharm Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after buying an additional 5,586 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Karyopharm Therapeutics by 10.1% during the second quarter. State Street Corp now owns 511,920 shares of the company’s stock worth $4,631,000 after buying an additional 47,127 shares in the last quarter. Institutional investors and hedge funds own 59.10% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.